BGC
EPRX

Beutel, Goodman & Co’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Beutel, Goodman & Co’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.4M Sell
3,666,465
-42,908
-1% -$345K 0.18% 62
2025
Q4 		$27.9M Sell
3,709,373
-349,526
-9% -$2.15M 0.17% 56
2025
Q3 		$23.9M Buy
+4,058,899
New +$22.1M 0.14% 56

Other funds holding EPRX

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Beutel, Goodman & Co's EPRX Position: Q1 2026 in Review

Beutel, Goodman & Co reduced its Eupraxia Pharmaceuticals (EPRX) stake by 1.2% in Q1 2026, selling an estimated $345K and leaving 3,666,465 shares worth $26.4M. The position accounts for 0.18% of the portfolio, ranked #62.

Beutel, Goodman & Co first reported a position in EPRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $27.9M in Q4 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Beutel, Goodman & Co held 3,666,465 shares of Eupraxia Pharmaceuticals worth $26.4M as of Q1 2026.
  • Beutel, Goodman & Co sold 42,908 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $345K.
  • Eupraxia Pharmaceuticals made up 0.18% of Beutel, Goodman & Co's portfolio in Q1 2026, its #62 holding.
  • Beutel, Goodman & Co first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Beutel, Goodman & Co's Eupraxia Pharmaceuticals position peaked at $27.9M in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Beutel, Goodman & Co's 13F filing for Q1 2026, filed 15 May 2026.